• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?
【24h】

Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?

机译：抗CD20治疗（利妥昔单抗）治疗原发性干燥综合征。可行的方法还是仅仅是起点？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: In vitro and in vivo experimental data have suggested new immunopathogenic mechanisms in primary Sjogren's syndrome (pSS). The availability of targeted treatment modalities has opened new ways to selectively target these mechanistic pathways in vivo. Amongst these new treatment modalities, monoclonal antibodies specific for the B-cell surface molecule CD20 have been shown to be the most promising treatment option to date. AREAS COVERED: A search of the Pubmed, MEDLINE, EMBASE, Cochrane and Ovid databases was performed to review literature on the efficacy and safety profile of anti-CD20 therapy in pSS patients. EXPERT OPINION: A single course of the chimeric humanized anti-CD20 antibody rituximab was effective in reducing disease activity in pSS patients for about six to nine months. Retreatment of responders resulted in a similar effect to initial treatment. When combined with corticosteroids during infusion, rituximab was shown to be a safe drug to administer. Thus, anti-CD20 therapy can be considered an effective treatment option in pSS patients. However, large randomized controlled trials with anti-CD20 therapy, for example rituximab, are warranted in order to: 1) assess long-term effects of such treatment, 2) determine which pSS patients will benefit most from anti-CD20 treatment and 3) assess which retreatment schedule should be followed.
机译：引言：体外和体内实验数据表明原发性干燥综合征（pSS）的新的免疫致病机制。靶向治疗方式的可获得性开辟了新的途径，以选择性地靶向体内这些机制途径。在这些新的治疗方式中，对B细胞表面分子CD20特异的单克隆抗体已被证明是迄今为止最有希望的治疗选择。覆盖的领域：对Pubmed，MEDLINE，EMBASE，Cochrane和Ovid数据库进行了检索，以回顾有关抗CD20治疗pSS患者的疗效和安全性的文献。专家意见：单一疗程的嵌合人源化抗CD20抗体利妥昔单抗可有效降低pSS患者的疾病活动约6至9个月。应答者的重新治疗与初始治疗产生相似的效果。在输注期间与皮质类固醇合用时，利妥昔单抗被证明是一种安全的药物。因此，抗CD20治疗可被视为pSS患者的有效治疗选择。但是，有必要使用抗CD20治疗（例如利妥昔单抗）进行大型随机对照试验，以：1）评估此类治疗的长期效果; 2）确定哪些pSS患者将从抗CD20治疗中受益最大; 3）评估应遵循的治疗时间表。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号